Zenas Biopharma (usa), Llc

This large, late-stage study is testing whether the drug orelabrutinib can slow or stop the worsening of disability in people with a specific form of progressive multiple sclerosis (MS) who have not had recent relapses. About 990 participants worldwide will receive either the stu…